Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
Learn more today.
Bobak R. Azamian net worth and biography

Bobak Azamian Biography and Net Worth

Bobby has served as President and CEO of Tarsus Pharmaceuticals since co-founding the company in 2017. In that time, Tarsus has established a leading team and culture, and completed successful fundraising efforts through an IPO and global partnerships. Tarsus continues to advance its pipeline into clinical studies, including its lead product, TP-03, which is now in Phase 3 clinical trials and commercial planning.

Bobby also serves on the board and is Co-Chairman of Vibrato Medical, a medical device company developing a wearable treatment for peripheral arterial diseases, which has received NIH grant awards and generated first-in-human proof of concept clinical data. Previously, he was President and CMO of Metavention, a medical device company developing an interventional treatment for metabolic diseases, from inception through proof of concept clinical trials as well as Series A through Series C fundraising.

Bobby began his biotechnology career at Versant Ventures and Third Rock Ventures, where he was an investor and board observer in numerous life sciences companies. He also served on the board of the nonprofit organization Octane.

He trained as a physician scientist, completing his residency in internal medicine and serving as an attending hospitalist at Brigham and Women’s Hospital. He received an MD from Harvard Medical School (Harvard-MIT Heath Sciences and Technology), a PhD in chemistry from Oxford University as a Rhodes Scholar, and a BA in physics from Rice University. He is also an author of numerous patents and peer-reviewed publications.

What is Bobak R. Azamian's net worth?

The estimated net worth of Bobak R. Azamian is at least $13.95 million as of March 15th, 2023. Dr. Azamian owns 1,080,536 shares of Tarsus Pharmaceuticals stock worth more than $13,949,720 as of March 21st. This net worth estimate does not reflect any other assets that Dr. Azamian may own. Learn More about Bobak R. Azamian's net worth.

What is Bobak R. Azamian's salary?

As the CEO of Tarsus Pharmaceuticals, Inc., Dr. Azamian earned a total compensation package of $6,870,723.00 in 2021. Dr. Azamian earned a salary of $550,000.00, a bonus of $269,500.00, options awards of $6,029,589.00, and other compensation of $21,634.00. Learn More on Bobak R. Azamian's salary.

How do I contact Bobak R. Azamian?

The corporate mailing address for Dr. Azamian and other Tarsus Pharmaceuticals executives is , , . Tarsus Pharmaceuticals can also be reached via phone at 949-409-9820 and via email at [email protected] Learn More on Bobak R. Azamian's contact information.

Has Bobak R. Azamian been buying or selling shares of Tarsus Pharmaceuticals?

Within the last three months, Bobak R. Azamian has sold $590,776.05 in shares of Tarsus Pharmaceuticals stock. Most recently, Bobak R. Azamian sold 8,000 shares of the business's stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $13.79, for a transaction totalling $110,320.00. Following the completion of the sale, the chief executive officer now directly owns 1,080,536 shares of the company's stock, valued at $14,900,591.44. Learn More on Bobak R. Azamian's trading history.

Who are Tarsus Pharmaceuticals' active insiders?

Tarsus Pharmaceuticals' insider roster includes D. Ackermann (Director), Bobak Azamian (CEO), and Aziz Mottiwala (Insider). Learn More on Tarsus Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Tarsus Pharmaceuticals?

During the last year, Tarsus Pharmaceuticals insiders bought shares 2 times. They purchased a total of 118,400 shares worth more than $1,646,608.00. During the last year, insiders at the sold shares 33 times. They sold a total of 200,369 shares worth more than $3,037,765.74. The most recent insider tranaction occured on March, 16th when VP Mark J Holdbrook sold 187 shares worth more than $2,511.41. Insiders at Tarsus Pharmaceuticals own 24.7% of the company. Learn More about insider trades at Tarsus Pharmaceuticals.

Information on this page was last updated on 3/16/2023.

Bobak R. Azamian Insider Trading History at Tarsus Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2023Sell8,000$13.79$110,320.001,080,536View SEC Filing Icon  
3/8/2023Sell4,853$15.02$72,892.061,089,253View SEC Filing Icon  
2/8/2023Sell9,000$15.14$136,260.001,102,106View SEC Filing Icon  
1/23/2023Sell4,856$15.45$75,025.201,111,106View SEC Filing Icon  
1/20/2023Sell240$15.00$3,600.001,116,373View SEC Filing Icon  
1/18/2023Sell8,000$14.56$116,480.001,116,613View SEC Filing Icon  
1/11/2023Sell3,904$15.11$58,989.441,124,613View SEC Filing Icon  
1/9/2023Sell729$15.15$11,044.351,129,422View SEC Filing Icon  
1/6/2023Sell411$15.00$6,165.001,129,740View SEC Filing Icon  
12/21/2022Sell8,000$14.57$116,560.001,130,151View SEC Filing Icon  
12/16/2022Sell535$15.01$8,030.351,138,151View SEC Filing Icon  
12/14/2022Sell6,420$15.08$96,813.601,138,686View SEC Filing Icon  
10/19/2022Sell8,000$16.92$135,360.001,162,106View SEC Filing Icon  
10/12/2022Sell9,000$15.91$143,190.001,170,106View SEC Filing Icon  
9/21/2022Sell8,000$16.31$130,480.001,179,106View SEC Filing Icon  
9/14/2022Sell9,000$16.01$144,090.001,187,106View SEC Filing Icon  
8/17/2022Sell8,000$16.59$132,720.001,196,106View SEC Filing Icon  
10/12/2021Sell5,531$26.30$145,465.30View SEC Filing Icon  
10/8/2021Sell302$25.02$7,556.04View SEC Filing Icon  
8/11/2021Sell1,917$25.07$48,059.191,750View SEC Filing Icon  
8/9/2021Sell827$25.02$20,691.541,750View SEC Filing Icon  
8/5/2021Sell1,370$25.00$34,250.00View SEC Filing Icon  
See Full Table

Bobak R. Azamian Buying and Selling Activity at Tarsus Pharmaceuticals

This chart shows Bobak R Azamian's buying and selling at Tarsus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tarsus Pharmaceuticals Company Overview

Tarsus Pharmaceuticals logo
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $12.91
Low: $12.74
High: $13.19

50 Day Range

MA: $15.04
Low: $12.75
High: $16.27

2 Week Range

Now: $12.91
Low: $10.80
High: $19.66


18,823 shs

Average Volume

73,014 shs

Market Capitalization

$344.31 million

P/E Ratio


Dividend Yield



Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
Learn more today.